Firm assists Recordati in the negotiation of the exclusive rights to license Graspa from Erytech.
On November 28, Willkie client Recordati announced that its subsidiary Orphan Europe and Erytech Pharma, a French biopharmaceutical company, have entered into an agreement granting Orphan Europe the exclusive rights for the commercialization and distribution of Graspa® for the treatment of Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe.
Founded in 1990, Orphan Europe was acquired by Recordati in 2007, focusing on orphan oncology and rare diseases. Graspa is a new formulation of L-asparaginase with a safer and broader range of clinical use than existing forms due to the entrapment and protection of the enzyme inside homologous red blood cells.
The matter was handled by partners Eduardo Fernandez and Daniel Hurstel and associates David Lambert and Liza Scemama.